Sign Up Today and Learn More About NextPoint Therapeutics Stock
Invest in or calculate the value of your shares in NextPoint Therapeutics or other pre-IPO companies through EquityZen's platform.

NextPoint Therapeutics Stock (NETH)
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients.
About NextPoint Therapeutics Stock
Founded
2020
Headquarters
Cambridge, MA, US
Industries
Software, Artificial Intelligence, Financial Services
NextPoint Therapeutics Press Mentions
Stay in the know about the latest news on NextPoint Therapeutics
Antibody-drug conjugates
patents • May 04, 2025
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
morningstar • Apr 26, 2025
NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025
businesswire • Apr 26, 2025
Kir3dl3 inhibitors and immune cell activating agents
patents • Apr 02, 2025
T cell and nk cell engagers
patents • Apr 02, 2025
NextPoint Therapeutics Management
Leadership team at NextPoint Therapeutics
Scientific Co-Founder
Xingxing Zang
Scientific Co-Founder
Gordon Freeman

Join now and verify your accreditation status to gain access to:
- NextPoint Therapeutics Current Valuation
- NextPoint Therapeutics Stock Price
- NextPoint Therapeutics Management
- Available deals in NextPoint Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- NextPoint Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- NextPoint Therapeutics Revenue and Financials
- NextPoint Therapeutics Highlights
- NextPoint Therapeutics Business Model
- NextPoint Therapeutics Risk Factors
- NextPoint Therapeutics Research Report from SACRA Research
Trading NextPoint Therapeutics Stock
How to invest in NextPoint Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like NextPoint Therapeutics through EquityZen funds. These investments are made available by existing NextPoint Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell NextPoint Therapeutics stock?
Shareholders can sell their NextPoint Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."